Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NUS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Dietary Supplement: LifePak Nano | Skin Diseases | N/A · NCT00541931 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NUS holds $166.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NUS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| American Century Investment Management, | Institution (13G, 5%+) | 2,691,940 | 5.53% | 2026-09-30 |
| Ryan S Napierski President and CEO, Director |
Insider | 1,001,905 | 2.06% | 2026-03-06 |
| Chayce David Clark EVP, COO and CLO |
Insider | 390,746 | 0.80% | 2026-03-06 |
| James D Thomas Chief Financial Officer |
Insider | 267,102 | 0.55% | 2026-03-06 |
| Steven Keith Hatchett Chief Product Officer |
Insider | 260,818 | 0.54% | 2026-03-06 |
| Justin S Keisel EVP, President of Global Sales |
Insider | 160,170 | 0.33% | 2026-03-06 |
| Daniel W Campbell Director |
Insider | 129,244 | 0.27% | 2026-06-01 |
| Pisano R. Thomas Director |
Insider | 116,827 | 0.24% | 2026-06-01 |
| Edwina D Woodbury Director |
Insider | 62,474 | 0.13% | 2026-09-09 |
| Mark A Zorko Director |
Insider | 60,586 | 0.12% | 2026-06-01 |
| Emma S. Battle Director |
Insider | 57,648 | 0.12% | 2026-06-01 |
| Laura Nathanson Director |
Insider | 57,116 | 0.12% | 2026-06-01 |
Share count 48,678,057 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NUS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →